Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2011-08-11 Director's Dealing
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2011-08-11 English
4 Filing
Director's Dealing
2011-08-10 English
8-K Filing
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and states that the company issued a press release announcing its financial results for the quarter ended June 30, 2011. The document includes the press release as Exhibit 99.1. The length of the document is 2918 characters, which is relatively short and mainly serves to announce the earnings release rather than provide detailed financial statements or analysis. According to the rules, initial announcements of quarterly financial results (key highlights only) are classified as Earnings Release (ER). This document fits that description as it announces the earnings release via a press release attached as an exhibit.
2011-08-08 English
10-Q Filing
Interim / Quarterly Report Q2 2011
2011-08-08 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated July 26, 2011. It includes a press release as an exhibit regarding positive clinical trial data from a partner company. The document is short (2901 characters) and primarily serves as an announcement of an event rather than a detailed financial report or earnings release. The content is a regulatory filing to disclose material information promptly, typical of Form 8-K filings. There is no detailed financial data, management discussion, or comprehensive report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2011-07-26 English
4 Filing
Director's Dealing
2011-07-26 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.